| Rewiring Yarrowia lipolytica toward triacetic acid lactone for materials generation KA Markham, CM Palmer, M Chwatko, JM Wagner, C Murray, S Vazquez, ... Proceedings of the National Academy of Sciences 115 (9), 2096-2101, 2018 | 168 | 2018 |
| Tumor intrinsic PD-L1 promotes DNA Repair in distinct cancers and suppresses PARP inhibitor–induced synthetic lethality AVR Kornepati, JT Boyd, CE Murray, J Saifetiarova, B de la Peña Avalos, ... Cancer research 82 (11), 2156-2170, 2022 | 30 | 2022 |
| Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice MG Garcia, Y Deng, C Murray, RM Reyes, A Padron, H Bai, A Kancharla, ... Aging and cancer 3 (1), 68-83, 2022 | 8 | 2022 |
| Pharmacologic tumor PDL1 depletion with cefepime or ceftazidime promotes DNA damage and sensitivity to DNA-damaging agents C Murray, E Galvan, C Ontiveros, Y Deng, H Bai, AS Padron, ... International journal of molecular sciences 23 (9), 5129, 2022 | 6 | 2022 |
| 900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner A Kornepati, C Murray, B Avalos, C Rogers, K Ramkumar, H Gupta, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 2 | 2021 |
| Tumor-intrinsic PD-L1 regulates tumor initiating cell virulence and stemness genes, and TCF1+ stem-like T cells through Raptor in ovarian cancer, which correlates with survival … HB Gupta, CE Murray, J Deng, TAS Mohammad, X Zhang, B Wu, ... The Journal of Immunology 202 (1_Supplement), 195.29-195.29, 2019 | 2 | 2019 |
| Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1 … H Bai, AS Padron, Y Deng, YJ Liao, CJ Murray, C Ontiveros, SJ Kari, ... Journal for Immunotherapy of Cancer 11 (2), 2023 | 1 | 2023 |
| PHARMACOLOGIC TUMOR PD-L1 DEPLETION WITH CHLORAMBUCIL TREATS OVARIAN CANCER AND MELANOMAS IN A TUMOR PD-L1-DEPENDENT MANNER AND RENDERS alpha PD-L1-RESISTANT TUMORS alpha PD-L1 … H Bai, A Padron, Y Deng, A Kornepati, S Polusani, S Kari, C Murray, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 9, A261-A261, 2021 | 1 | 2021 |
| 1488 Melanoma cell-of-origin PDL1 promotes early tumor progression and distinct immune outcomes in a novel autochthonous NRAS-mutant melanoma model C Ontiveros, C Murray, H Bai, MJ Turk, T Curiel Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Considerations and Approaches for Cancer Immunotherapy in the Aging Host CO Ontiveros, CE Murray, G Crossland, TJ Curiel Cancer Immunology Research 11 (11), 1449-1461, 2023 | | 2023 |
| Pharmacologic tumor PDL1 depletion as a novel approach to overcome treatment resistance C Murray, H Bai, CO Ontiveros, P Blinkiewicz, E Galvan, Y Deng, ... The Journal of Immunology 210 (1_Supplement), 230.08-230.08, 2023 | | 2023 |
| Melanocyte PDL1 promotes early tumor progression in a novel autochthonous NRAS-mutant melanoma model CO Ontiveros, T Chen, C Murray, A Kornepati, Y Deng, P Blinkiewicz, ... The Journal of Immunology 210 (1_Supplement), 88.11-88.11, 2023 | | 2023 |
| 1428 Melanocyte-intrinsic PDL1 promotes tumorigenesis and progression in a novel autochthonous melanoma model C Ontiveros, Y Deng, A Kornepati, C Murray, MJ Turk, H Gupta, A Padron, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 501 Anti-PDL2 uses IL17-driven interferon-gamma to treat aged but not young cutaneous melanoma-bearing mice, and treats other tumors in an age-and TME-dependent manner M Garcia, Y Deng, C Murray, C Ontiveros, A Padron, S Skopelja-Gardner, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 453 Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities C Murray, H Bai, A Kornepati, C Ontiveros, Y Deng, A Padron, E Galvan, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 421 Specific cephalosporin antibiotics deplete tumor PD-L1 to inhibit DNA damage sensing and sensitize to Chk1 inhibitors in vivo C Murray, A Kornepati, A Padron, Y Deng, M Garcia, H Bai, T Curiel Journal of Clinical and Translational Science 6 (s1), 82-82, 2022 | | 2022 |
| 242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive H Bai, Á Padrón, Y Deng, A Kornepati, S Polusani, K Suresh, C Murray, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A261-A261, 2021 | | 2021 |
| 755 Pharmacologic tumor PD-L1 depletion reduces Chk2 content and sensitizes tumors to small molecule Chk1 DNA damage repair inhibitors C Murray, A Kornepati, A Padron, M Garcia, H Bai, Y Deng, T Curiel Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| Intracellular PD-L1 regulates DNA damage checkpoints and suppresses Chk1 and PARP inhibitor synthetic lethality AV Kornepati, Y Deng, E Dray, C Murray, SC Kari, E Osta, Z Liu, J Boyd, ... The Journal of Immunology 206 (1_Supplement), 67.15-67.15, 2021 | | 2021 |
| Engineering Yarrowia Lipolytica for the Production of Triacetic Acid Lactone K Markham, C Palmer, C Murray, H Alper 2017 AIChE Annual Meeting, 2017 | | 2017 |
Tyler CurielDartmouth Health and Geisel School of Medicine at DartmouthVerified email at dartmouth.edu
